Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (£272m) spanning five years due to Washington's request for sensitive information.
This move was revealed after a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the deal was "lopsided".
An official representative has since clarified that the US was demanding access to biological samples for scientific study and profit but was not willing to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more dialogue to secure a deal agreeable to all parties so the country's critical HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court suspended a similar health funding agreement after concerns were raised about the safety of citizens' health data.
After resuming office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing government-to-government deals to boost transparency and responsibility.
According to statements, 16 African countries have to date agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Declined Agreement
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy via American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, without any equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Put simply, our country would supply the raw materials for medical research without any certainty that the final treatments would be accessible to our people should a future pandemic emerge."
National Interest and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending structures already set up through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This system is designed to guarantee that when a country contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage further discussions with our American counterparts on how subsequent co-operation could be designed in a way that respects the sovereignty and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that talks need to persist given that much of the country's Aids initiatives depended on international support.
"If specific concerns arise, such as those involving data governance or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
The situation underscores the complex debate between receiving crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.